L-748,337
Biological Activity
Competitive β3-adrenoceptor antagonist that displays selectivity over β1 and β2 receptors (Ki values are 4.0, 204 and 390 nM for β3-, β2- and β1-adrenoceptors respectively). Inhibits cAMP accumulation in response to isoproterenol (IC50 = 6 nM). Reduces iNOS expression, attenuates nitric oxide-induced cell proliferation and induces apoptosis in a melanoma cell line.
Technical Data
| M. Wt | 497.61 |
| Formula | C26H31N3O5S |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 244192-94-7 |
| PubChem ID | 10028830 |
| InChI Key | AWIONHVPTYTSHZ-DEOSSOPVSA-N |
| Smiles | O[C@H](COC2=CC=CC(CNC(C)=O)=C2)CNCCC1=CC=C(NS(=O)(C3=CC=CC=C3)=O)C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 49.76 | 100 | |
| ethanol | 12.44 | 25 |
Preparing Stock Solutions
The following data is based on the product molecular weight 497.61. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.01 mL | 10.05 mL | 20.1 mL |
| 5 mM | 0.4 mL | 2.01 mL | 4.02 mL |
| 10 mM | 0.2 mL | 1 mL | 2.01 mL |
| 50 mM | 0.04 mL | 0.2 mL | 0.4 mL |
Molarity Calculator
Reconstitution Calculator
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Candelore et al (1999) Potent and selective human β3-adrenergic receptor antagonist. J.Pharmacol.Exp.Ther. 290 649 PMID: 10411574
Neidhold et al (2007) The function of α- and β-adrenoceptors of the saphenous artery in caveolin-1 knockout and wild-type mice. Br.J.Pharmacol. 150 261 PMID: 17179950
Dal Monte et al (2014) β3-adrenergic receptor activity modulates melanoma cell proliferation and survival through nitric oxide signaling. Naunyn Schmiedebergs Arch.Pharmacol. 387 533 PMID: 24599317
If you know of a relevant reference for L-748,337, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: L-748,337, supplier, Selective, β3-adrenoceptor, b3-adrenoceptor, antagonists, β3-adrenergic, b3-adrenergic, Receptors, Adrenoceptors, L748337, Adrenergic, Beta-3, Receptors, Adrenergic, Beta-3, Receptors, Tocris Bioscience
Citations for L-748,337
Citations are publications that use Tocris products.
Currently there are no citations for L-748,337. Do you know of a great paper that uses L-748,337 from Tocris? If so please let us know.
Literature in this Area
Cardiovascular Research Product Guide
A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:
- Hypertension
- Thrombosis and Hemostasis
- Atherosclerosis
- Myocardial Infarction
- Ischemia/Reperfusion Injury
- Arrhythmias
- Heart Failure
GPCR Product Listing
A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:
- Rhodopsin-like Receptors
- Secretin-like Receptors
- Glutamate Receptors
- Frizzled Receptors
- GPCR Signaling
Cardiovascular Poster
Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
